PreOmics, a Martinsried, Germany-based company that develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry, raised €3.3m in series A funding.
The round was led by Think.Health Ventures with participation from High-Tech Gründerfonds and business angels.
The company intends to use the funfs for the continued internationalization of the business and the development of further products.
Co-founded by Garwin Pichler and Nils Kulak in August 2016 with Intellectual Property from Matthias Mann’s laboratory at the Max Planck Institute for Biochemistry, PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry.
PreOmics addresses these problems with a standardized technology that enables reproducible results in sample preparation. In addition, the protocols have a reduced workload compared to conventional methods.